NOV 0 3-2003 W S TRADEMARK TORNEY Docket No. 8325-2008 (G8-US1)

1645

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on /o/24/03

y: Yang Tang

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of CHOO et al.

Serial No.: 09/996,484

09/996,484 Examiner: Unassigned

Confirmation No.: 2713

Art Unit: 1645

RECEIVED

Filed:

November 28, 2001

NOV 0 6 2003

For:

MOLECULAR SWITCHES

TECH CENTER 1600/2900

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

[X]	the IDS is required.					
[]	In accordance with 37 C.F.R. §1.97(c), also enclosed is:					
	[] the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or					
	[] a statement as specified in 37 C.F.R. §1.97(e).					
[]	In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p)					

are also enclosed.

[] Check No. __ in the amount of \$__ for the total fee is attached.

- [X] A return receipt postcard is also enclosed.
- [] Please charge \$____ to Deposit Account No. 18-1648 for the total fee. This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Dated: 00 22/03

Respectfully submitted,

Robins & Pasternak LLP 1731 Embarcadero Road, Suite 230

Palo Alto, CA 94303 Tel: (650) 493-3400 Fax: (650) 493-3440 By:

Dahna S. Pasternak Reg. No. 41,411

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 450, Alexandria, VA 22313-1450 on 10/24/03.

By: June 7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of CHOO et al.

Serial No.: 09/996,484

Examiner: Unassigned

RECEIVED

Confirmation No.:

2713

Art Unit: 1645

NOV 0 6 2003

TECH CENTER 1600/2900

Filed:

November 28, 2001

For:

MOLECULAR SWITCHES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §\$1.97 and 1.98.

- [X] Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- [] No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. ___ to which the above-identified application claims priority under 35 U.S.C. §120.
- [X] Publication(s) <u>B1-15</u>, <u>C1-3</u>, <u>C5</u> listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to <u>PCT</u> application serial no. <u>PCT/GB00/02080</u> and mailed on <u>October 10</u>, 2000.
- [X] Publication(s) <u>B3, B6, B13, C1-5</u> listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report

		corresponding to <u>PCT</u> application serial no. <u>PCT/GB00/02071</u> and mailed on <u>October 10, 2000</u> .					
	[]	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).					
	[]	Enclosed is a copy of a non-English publication(s) English language publication (copy enclosed) claims priority from this non-English publication.					
	[] Enclosed is an explanation of non-English publication(s) for which an English translation is not available.						
	[] Enclosed is an English translation of non-English publication(s)cited in the attached Form PTO/SB/08A.						
	[]	Enclosed is a copy of pending patent Application Serial No					
time pe		formation Disclosure Statement is filed within any one of the following					
	[] within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);						
	 [] within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application; [X] before the mailing date of a first office action on the merits; or 						
	[] before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.						
	It is res	spectfully requested that the Examiner consider the above-noted					
inform	ation an	nd return an initialed copy of the attached Form PTO/SB/08A to the					
unders	igned.						
Dated:	0d	Respectfully submitted,					
1731 E Palo A Tel: (6		-3400 By: Manual By: Dahna S. Pasternak					
		Reg. No. 41,411					

Complete if Known bstitute for form 1449A/PTO **Application Number** 09/996,484 INFORMATION DISCLOSURE November 28, 2001 **Filing Date** STATEMENT BY APPLICANT First Named Inventor CHOO Group Art Unit 1645 (use as many sheets as necessary) **Examiner Name** Unassigned Sheet 1 of 2 Attorney Docket Number 8325-2008 (G8-US1)

U.S. PATENT DOCUMENTS						
Examiner Initials*		U.S. Paten	t Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	Cite No.1	Number	Kind Code ² (if known)			
<u></u>						
		· · · · · · · · · · · · · · · · · · ·				
u	 		· ·			
						

Office WO WO WO WO WO WO WO	92/00388 93/23431 94/29442 95/20652 96/01313 96/06166 96/20951 96/40892	Kind Code ⁵ (if known) A1 A1 A2 A1 A1 A1	Name of Patentee or Applicant of Cited Document The Regents of the University of California Baylor College of Medicine BASF Aktiengesellschaft Altmann, Herbert Bujard, Hermann Medical Research Council Massachusetts Institute of Technology	of Cited Document MM-DD-YYYY 01-09-1992 11-25-1993 12-22-1994 08-03-1995 01-18-1996 02-29-1996 07-11-1996	T ⁶
WO WO WO WO WO WO	93/23431 94/29442 95/20652 96/01313 96/06166 96/20951	A1 A2 A1 A1 A1	Baylor College of Medicine BASF Aktiengesellschaft Altmann, Herbert Bujard, Hermann Medical Research Council	11-25-1993 12-22-1994 08-03-1995 01-18-1996 02-29-1996	
WO WO WO WO WO	94/29442 95/20652 96/01313 96/06166 96/20951	A2 A1 A1 A1 A1	BASF Aktiengesellschaft Altmann, Herbert Bujard, Hermann Medical Research Council	12-22-1994 08-03-1995 01-18-1996 02-29-1996	•
WO WO WO WO	95/20652 , 96/01313 96/06166 96/20951	A1 A1 A1 A1	Altmann, Herbert Bujard, Hermann Medical Research Council	08-03-1995 01-18-1996 02-29-1996	
WO WO WO	96/01313 96/06166 96/20951	A1 A1 A1	Bujard, Hermann Medical Research Council	01-18-1996 02-29-1996	
WO WO WO	96/06166 96/20951	A1 A1	Medical Research Council	02-29-1996	
WO WO	96/20951	A1			
WO			Massachusetts Institute of Technology	07-11-1996	
	96/40892			07 11 1220	
****	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	A1	BASF AG	12-19-1996	
wo	96/41865	A1	Ariad Gene Therapeutics, Inc.	12-27-1996	
wo	97/10337	Al	Baylor College of Medicine	03-20-1997	
wo	97/31113	A1	Ariad Pharmaceuticals, Inc.	08-28-1997	
WO	98/25947	Al	Bristol-Myers Squibb Company	06-18-1998	
	98/53057	Al	Medical Research Council	11-26-1998	
	99/01549	A1	BASF Aktiengesellschaft	01-14-1999	
	99/10510	A2	Ariad Gene Therapeutics, Inc.	03-04-1999	
wo	00/73434	A1	Gendaq Limited	12-07-2000	
_				- 	
	WO WO WO	WO 98/25947 WO 98/53057 WO 99/01549 WO 99/10510	WO 98/25947 A1 WO 98/53057 A1 WO 99/01549 A1 WO 99/10510 A2 WO 00/73434 A1	WO 98/25947 A1 Bristol-Myers Squibb Company WO 98/53057 A1 Medical Research Council WO 99/01549 A1 BASF Aktiengesellschaft WO 99/10510 A2 Ariad Gene Therapeutics, Inc. WO 00/73434 A1 Gendaq Limited	WO 98/25947 A1 Bristol-Myers Squibb Company 06-18-1998 WO 98/53057 A1 Medical Research Council 11-26-1998 WO 99/01549 A1 BASF Aktiengesellschaft 01-14-1999 WO 99/10510 A2 Ariad Gene Therapeutics, Inc. 03-04-1999 WO 00/73434 A1 Gendaq Limited 12-07-2000

Examiner	 Date	
Signature	 Considered	<u></u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

NO) TP	75.38 30HH	ype a plus sign (+) inside this box →	+
(A	TRADE	MANA		

	hatitude for former 1440D/DTO			Complete if Kno	wn	
`	Substitute for form 1449B/PTO			Application Number	09/996,484	BECEIVED
,	TENTA TO BE A TITLE			Filing Date	November 28, 2001	
	INFORMATI			First Named Inventor	СНОО	11011 0 1 0000
STATEMENT BY APPLICANT				Group Art Unit	1645	NOV 0 ° 2003
1	,	, .		Examiner Name	Unassigned	
(use as many sheets as necessary)			necessary)			- TECH CENTER 1600/290
Sheet	2	of	2	Attorney Docket Number	8325-2008 (G8-US1)	IEON OF MIEW 1000/500

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	C1	Dickinson et al., "Inhibition of RNA Polymerase II Transcription in Human Cells by Synthetic DNA-Binding Ligands," PNAS 95(22):12890-12895 (1998)					
	C2	Dickinson et al., "Inhibition of Ets-1 DNA Binding and Ternary complex Formation Between Ets-1, NF-KappaB, and DNA by a Designed DNA-Binding Ligand," <i>Journal of Biological Chemistry</i> 274(18):12765-12773 (1999)					
	C3	Gatz et al., "Stringent Repression and Homogenous De-Repression by Tetracycline of a Modified CaMV 355 Promoter in Intact Transgenic Tobacco Plants," Plant Journal 2(3):397-404 (1992)					
	C4	Gottesfed et al, "Regulation of Gene Expression by Small Molecules," Nature 387(6629):202-205 (1997)					
	C5 .	Weinmann et al., "Chimeric Transactivator Allows Tetracycline-Responsive Gene Expression in Whole Plants," <i>Plant Journal</i> 5(4):559-569 (1994)					
		· ·					

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 Applicant is to place a check mark here if English language Translation attached.